Jan 8, 2015
Intezyne Technologies Announces Formation of its Clinical Advisor Board
July 10, 2014
Intezyne Technologies Expands Executive Leadership Team with Two Key Appointments
Intezyne’s IT-235 is a first-in-class targeted gallium-based small molecule administered as oral tablets once daily.
Intezyne, Inc. believes the IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy.